Brief Introduction

Founded in 2009, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Zelgen)is located in the Kunshan National New and High-Tech District in Kunsan, Jiangsu, China. Zelgen is one of leading biopharmaceutical companies in China and focus on drug discovery, development and commercialization of new medicines. With the primary business interest in oncology, hematology, bleedingand inflammatory autoimmune diseases, Zelgen has successfully built a strong leader team with global pharmaceutical industrial experiences, cutting-edge technology platforms for small molecule and large molecule drug discovery and development, a differential and competitive pipelineand sales and marketing team.Zelgen has five subsidiaries, US Gensun Biopharma Inc., Shanghai Zelgen Pharma-Tech Co. Ltd., Suzhou Zelgen Biosciences Co. Ltd., Zelgen Pharmaceuticals (Zhejiang) Co., Ltd.and Zelgen Hongkong Holding Ltd. Although the company has its primary market for Great Chinaarea, it is also actively expanding its business to worldwide. Zelgen, the first company IPO with the Fifth Standard in Shanghai STAR Market, has been well recognized as one of leaders of new generation of biopharmaceutical companies in China.

The developmentof a leading and proprietary pipeline is crucial forZelgen. Based on its two cutting-edge technology platforms, Zelgen has developed a solid and differential product pipeline composed of 13 new drug candidates and near 30clinical programs, which enable Zelgen covers multiple disease areas including liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, alopecia areata, ankylosing spondylitis, and atopic dermatitis et al. Its most advanced small molecule drug, Donafenib, has been proven superior to Sorafenib in a large phase 3 clinical trial for first line treatment of advanced liver cancer, which is the only TKI proven to be superior to Sorafenib in near a decade, and close to be approved for marketing by NMPA. Zelgen's Jaktinib and recombinant human thrombin as well as recombinant human TSH are also advanced to phase III clinical trials based on their successful phase 2 results. Same importantly, Zelgen has been developing its new generation of antitumor antibodies based on Gensun's superior bi/tri-specific antibody technique platforms, which confer Zelgen a global and long term competitive advantages. Zelgen has filed over 180 patent applications worldwide, of which 88patents have been issued in USA, EU, China and other countries till the end of 2020.

In addition, Zelgen has built two GMP plants for chemical tablets/capsules and recombinant proteinsin Kunshan, China. The production facilities conferthe company a great flexibility for the commercialization of its new drugs.

Company Overview

Full name Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Abbreviations Zelgen
Code 688266
Founded 2009.03.18
Listing 2020.01.23
Domicile Kunshan, Jiangsu Province
STAR Theme Biopharma
CSRC Sector Manufacturing
Has weighted voting rights structure? No



  2020 2019 2018
Earnings Per Share -1.36 -2.57 N/A
R&D expenditure as a % of operating revenue 1,135.89 N/A N/A
Operating Revenue 27.66 0 1.31
Net Income -310.68 -447.98 -441.88

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 27.66 0 1.31
Operating Costs 367.87 456.27 462.92
Operating Income -304.83 -439.79 -442.65
Pretax Income -304.83 -439.79 -442.66
Income Tax 5.84 8.20 -0.78
Net Income -310.68 -447.98 -441.88

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Current Assets-Total 1,669.57 101.82 229.67
Non-current Assets-Total 300.71 218.44 225.21
Total Assets 1,970.28 320.27 454.88
Current Liabilities-Total 140.87 150.17 77.56
Non-current Liabilities-Total 137.82 96.35 95.69
Total Liabilities 278.69 246.52 173.24
Stockholder's Equity
Share Capital 2,414.32 474.98 1,023.82
Retained Profits -796.60 -471.56 -797.51
Minority Interests 73.86 70.32 55.33
Total Owners' Equity 1,691.59 73.75 281.64

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating -343.86 -180.43 -112.44
Net Cash Flows-Investing -499.25 63.33 -53.11
Net Cash Flows-Financing 1,899.04 54.32 285.37

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
ZELIN SHENG 49.64 20.68%
宁波泽奥股权投资管理合伙企业(有限合伙) 16.50 6.88%
HUIPING LU 12.57 5.24%
石河子康润股权投资有限合伙企业 10.03 4.18%
昆山市工业技术研究院小核酸生物技术研究所有限责任公司 10.03 4.18%
苏州博澳股权投资合伙企业(有限合伙) 9.22 3.84%
宁波梅山保税港区璞石新兴股权投资合伙企业(有限合伙) 6.12 2.55%
As of 2020-12-31

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.